Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), has announced the appointment of pharmaceutical industry leader Robert J. Hugin to its board of directors, effective immediately. Hugin previously was chairman and chief executive officer of Celgene Corp., where he was instrumental in the strategic growth and global expansion of the company. Celgene was ultimately acquired by Bristol-Myers Squibb in 2019 for a total equity value of approximately $74 billion.
Said Biohaven board chair Declan Doogan, MD in announcing the appointment: “We are excited to welcome Bob to Biohaven’s board of directors as we have evolved to a commercial organization and look to the future. Having access to Bob’s astute business and financial acumen will help Biohaven achieve our goal of becoming the leading pharmaceutical company focused on neuroscience indications.”
Â
